These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33314293)

  • 1. Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
    Oshima S; Fushimi Y; Okada T; Nakajima S; Yokota Y; Shima A; Grinstead J; Ahn S; Sawamoto N; Takahashi R; Nakamoto Y
    Mov Disord; 2021 Apr; 36(4):874-882. PubMed ID: 33314293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease.
    He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X
    Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease.
    Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Liu T; Wang Y; Tomiyama N
    Br J Radiol; 2018 Jun; 91(1086):20180037. PubMed ID: 29498540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Gaurav R; Yahia-Cherif L; Pyatigorskaya N; Mangone G; Biondetti E; Valabrègue R; Ewenczyk C; Hutchison RM; Cedarbaum JM; Corvol JC; Vidailhet M; Lehéricy S
    Mov Disord; 2021 Jul; 36(7):1592-1602. PubMed ID: 33751655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive MRI quantification of the substantia nigra pars compacta in Parkinson's disease.
    Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Takahashi K; Yamamoto K; Liu T; Wang Y; Tomiyama N
    Eur J Radiol; 2018 Dec; 109():48-56. PubMed ID: 30527311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Black-blood multicontrast imaging of carotid arteries with DANTE-prepared 2D and 3D MR imaging.
    Li L; Chai JT; Biasiolli L; Robson MD; Choudhury RP; Handa AI; Near J; Jezzard P
    Radiology; 2014 Nov; 273(2):560-9. PubMed ID: 24918958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
    Langley J; He N; Huddleston DE; Chen S; Yan F; Crosson B; Factor S; Hu X
    Mov Disord; 2019 Mar; 34(3):416-419. PubMed ID: 30597635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.
    Xing Y; Sapuan A; Dineen RA; Auer DP
    Mov Disord; 2018 Nov; 33(11):1792-1799. PubMed ID: 30423212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atlas-based relaxometry and subsegment analysis of the substantia nigra pars compacta using quantitative MRI: a healthy volunteer study.
    Fujiwara Y; Ishida S; Matta Y; Kanamoto M; Kimura H
    Br J Radiol; 2022 Jul; 95(1135):20210572. PubMed ID: 35357890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.
    Hatano T; Okuzumi A; Kamagata K; Daida K; Taniguchi D; Hori M; Yoshino H; Aoki S; Hattori N
    J Neural Transm (Vienna); 2017 Apr; 124(4):407-415. PubMed ID: 28160151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach.
    Jokar M; Jin Z; Huang P; Wang Y; Zhang Y; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Min J; Liu F; Chen S; He N; Haacke EM; Yan F
    Neuroimage; 2023 Feb; 266():119814. PubMed ID: 36528314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging.
    Moon WJ; Park JY; Yun WS; Jeon JY; Moon YS; Kim H; Kwak KC; Lee JM; Han SH
    Korean J Radiol; 2016; 17(5):633-40. PubMed ID: 27587951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT.
    Takahashi H; Kashiwagi N; Arisawa A; Matsuo C; Kato H; Adachi H; Kajiyama Y; Mochizuki H; Tomiyama N
    Br J Radiol; 2022 Feb; 95(1130):20210837. PubMed ID: 34808066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist.
    De Pietro Franco Zorzenon C; Almeida Antônio Bienes GH; Duarte Alves E; Tobaru Tibana LA; Carrete Júnior H; Ballalai Ferraz H
    Parkinsonism Relat Disord; 2021 Feb; 83():8-12. PubMed ID: 33418131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.